Skip to main content

8110 Gatehouse Road, Falls Church, VA 22042

LIFE

General Information

Age Group

Adult

Status

Active

Protocol Number

NCT02816736

Background Information

This study seeks to evaluate the effectiveness of sacubatril-valsartan (aka: Entresto) in patients with advanced heart failure. 

This is a US, multicenter, placebo-controlled, HFrEF trial. Testing Entresto in patients with any history of NYHA IV symptoms. 26-week study to assess change in NT-proBNP. Sponsor: NIH HF Network.

Offered At

Inova Heart and Vascular Institute
3300 Gallows Road
Falls Church, VA 22042

Principal Investigator

Palak Shah, MD

Eligibility Information

  • 18 to 85 years old
  • Ejection fraction ≤ 35%
  • Advanced HF (any are ok):
    • Intropes > 4 days in past 6 months
    • 2 or more hospitalizations in 6 months
    • EF =< 25%
    • eGFR < 45
    • 6 minute walk < 300 m
    • VO2 < 55% predicted or =< 14 female or =< 16 male

Ineligibility Information

  • Age > 85 years
  • SBP < 90mmHg
  • Scheduled for LVAD within 30 days
  • Currently listed for heart transplant (1A or 1B ) and hospitalized

Contact Name

Bhruga Shah
703-776-2995
bhruga.shah@inova.org
or
Vinita Gupta
703-776-3697
vinita.gupta@inova.org
or
Call the main Advanced Heart Failure Research office at 703-776-2828